PHASE-II TRIALS OF INTERFERON-ALPHA AND INTERFERON-BETA IN ADVANCED SARCOMAS

被引:3
作者
BORDEN, EC
KIM, K
RYAN, L
BLUM, RH
SHIRAKI, M
TORMEY, DC
COMIS, RL
HAHN, RG
PARKINSON, DR
机构
[1] UNIV WISCONSIN,CTR CLIN CANC,MADISON,WI 53792
[2] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115
[3] NYU MED CTR,NEW YORK,NY 10016
[4] TUFTS UNIV,BOSTON,MA 02115
[5] FOX CHASE CANC CTR,PHILADELPHIA,PA 19111
[6] MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905
[7] NCI,BETHESDA,MD 20892
来源
JOURNAL OF INTERFERON RESEARCH | 1992年 / 12卷 / 06期
关键词
D O I
10.1089/jir.1992.12.455
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferons (IFNs)-alpha and -beta were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-alpha2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c. t.i.w. In the second study, patients received IFN-beta(ser) 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-alpha-2b and no responses in 23 patients treated with IFN-beta(ser). Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha2b and 17% of patients receiving IFN-beta(ser). Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies.
引用
收藏
页码:455 / 458
页数:4
相关论文
共 12 条
[1]   COMBINATION CHEMOTHERAPY USING ADRIAMYCIN, DTIC, CYCLOPHOSPHAMIDE, AND ACTINOMYCIN-D FOR ADVANCED SOFT-TISSUE SARCOMAS - A RANDOMIZED COMPARATIVE TRIAL - A PHASE-III, SOUTHWEST-ONCOLOGY-GROUP-STUDY (7613) [J].
BAKER, LH ;
FRANK, J ;
FINE, G ;
BALCERZAK, SP ;
STEPHENS, RL ;
STUCKEY, WJ ;
RIVKIN, S ;
SAIKI, J ;
WARD, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (06) :851-861
[2]   RANDOMIZED COMPARISON OF 3 ADRIAMYCIN REGIMENS FOR METASTATIC SOFT-TISSUE SARCOMAS [J].
BORDEN, EC ;
AMATO, DA ;
ROSENBAUM, C ;
ENTERLINE, HT ;
SHIRAKI, MJ ;
CREECH, RH ;
LERNER, HJ ;
CARBONE, PP .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (06) :840-850
[3]  
ELIAS A, 1990, SEMIN ONCOL, V17, P41
[4]  
GOLDSTEIN D, 1986, CANCER RES, V46, P4315
[5]   PHASE-II TRIAL OF CARBOPLATIN IN SOFT-TISSUE SARCOMA [J].
GOLDSTEIN, D ;
CHEUVART, B ;
TRUMP, DL ;
SHIRAKI, M ;
COMIS, RL ;
TORMEY, DC ;
HARRIS, JE ;
BORDEN, EC .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (05) :420-423
[6]  
HARRIS JE, 1985, P ASCO, V4, P222
[7]   INTERFERONS - BIOLOGICAL AND CLINICAL EFFECTS [J].
NELSON, BE ;
BORDEN, EC .
SEMINARS IN SURGICAL ONCOLOGY, 1989, 5 (06) :391-401
[8]   TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
OKEN, MM ;
CREECH, RH ;
TORMEY, DC ;
HORTON, J ;
DAVIS, TE ;
MCFADDEN, ET ;
CARBONE, PP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :649-655
[9]  
SCHOENFELD DA, 1982, CANCER, V50, P2757, DOI 10.1002/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO
[10]  
2-J